Prostacyclin and its analogues in pulmonary artery hypertension: A meta-analysis

Current Medical Research and Opinion

Volumn 29, Issue 8, 2013, Pages 889-899

  Li, Tiejun ^a   Chen, Yanli ^a   Zang, Weidong ^a   Geng, Ning ^a   Ma, Shumei ^a   Li, Xiaodong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Analogues; Meta analysis; Prostacyclin; Pulmonary artery hypertension

Indexed keywords

BERAPROST; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; TREPROSTINIL;

ARTICLE; CARDIOPULMONARY FUNCTION; DRUG EFFICACY; FOLLOW UP; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; META ANALYSIS; MONOTHERAPY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84880470790     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.802682     Document Type: Article

References (38)

1. Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64:583-620
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23 (Pubitemid 17137857)
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
4. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65 (Pubitemid 38114133)
5. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-17 (Pubitemid 27020889)
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65
7. Boutet K, Montani D, Jais X, et al. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2008;2:249-65
8. McGoon MD, Kane GC. Pulmonary hypertension: Diagnosis and management. Mayo Clin Proc 2009;84:191-207
9. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924
10. Paramothayan NS, Lasserson TJ, Wells AU, et al. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev 2005;(2):CD002994
11. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47 (Pubitemid 46809838)
12. He B, Zhang F, Li X, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010;74:1458-64
13. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010;104:9-21
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12 (Pubitemid 26120810)
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
16. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34 (Pubitemid 27387172)
17. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63 (Pubitemid 30422636)
18. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34 (Pubitemid 30149039)
19. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
20. Hache M, Denault A, Belisle S, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg 2003;125:642-9 (Pubitemid 36373912)
21. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91 (Pubitemid 20100285)
22. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4 (Pubitemid 46331988)
23. Kramm T, Eberle B, Guth S, et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005;28:882-8 (Pubitemid 41735269)
24. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63 (Pubitemid 44924827)
25. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9 (Pubitemid 34815354)
26. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010;104: 731-40
27. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9 (Pubitemid 36135255)
28. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22
29. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4 (Pubitemid 34229650)
30. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25 (Pubitemid 36724255)
31. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502 (Pubitemid 34439066)
32. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
33. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
34. Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 2012;141:642-50
35. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives. J Am Coll Cardiol 2004;43(12 Suppl S):48-55S (Pubitemid 38759717)
36. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-87
37. Steele P, Strange G, Wlodarczyk J, et al. Hemodynamics in pulmonary arterial hypertension (PAH): Do they explain long-term clinical outcomes with PAHspecific therapy? BMC Cardiovasc Disord 2010;10:9
38. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012;60:1192-201